Literature DB >> 15191312

Dose perturbation induced by radiographic contrast inside brachytherapy balloon applicators.

Michael C Kirk1, Wen C Hsi, James C H Chu, Honquan Niu, Zenan Hu, Damian Bernard, Adam Dickler, Cam Nguyen.   

Abstract

Phantom measurements and Monte Carlo calculations have been performed for the purpose of characterizing the dose perturbation caused by radiographic contrast inside the MammoSite breast brachytherapy applicator. Specifically, the dose perturbation is quantified as a heterogeneity correction factor (HCF) for various balloon radii and contrast concentration levels. The dose perturbation is larger for larger balloon radii and higher contrast concentrations. Based on a validated Monte Carlo simulation, the calculated HCF values are 0.99 for a 2 cm radius balloon and 0.98 for a 3 cm radius balloon at 6% contrast concentration levels, and 0.89 and 0.87 for 2 and 3 cm radius balloons, respectively, at 100% contrast concentrations. For a typical implanted balloon radius of 2.4 cm, the HCF values decrease from 0.99 at 6% contrast concentration to 0.90 at 100% contrast concentration. For balloons implanted in patients at our institution, the mean HCF is 0.99, corresponding to a dose reduction of approximately 1%. The contrast effect results in a systematic reduction in the delivered dose, therefore the minimal amount of radiographic contrast necessary should be used.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191312     DOI: 10.1118/1.1705445

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

1.  The impact of uncertainties associated with MammoSite brachytherapy on the dose distribution in the breast.

Authors:  Saleh Bensaleh; Eva Bezak
Journal:  J Appl Clin Med Phys       Date:  2011-11-15       Impact factor: 2.102

2.  A simulation study on using 252Cf for the treatment of esophagus tumor in human phantom.

Authors:  Fatemeh S Rasouli; Hasan Bakhshandeh; S Mohsen Salehkoutahi
Journal:  EJNMMI Phys       Date:  2020-12-03

3.  Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy.

Authors:  Christian Scherf; Ulla Ramm; Thomas Stein; Martin Trommel; Nikolaos Tselis; Georgios Chatzikonstantinou; Markus Diefenhardt; Claus Rödel; Janett Köhn; Jörg Licher
Journal:  J Contemp Brachytherapy       Date:  2022-02-18

4.  Dose correction in lung for HDR breast brachytherapy.

Authors:  Eric Slessinger; Eric Pepin; Qingya Zhao; Li Zhao; Indra Das
Journal:  J Contemp Brachytherapy       Date:  2012-06-30

Review 5.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

6.  Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source.

Authors:  Chang Hyun Choi; Sung-Joon Ye; E Ishmael Parsai; Sui Shen; Ruby Meredith; Ivan A Brezovich; Roger Ove
Journal:  J Appl Clin Med Phys       Date:  2009-02-03       Impact factor: 2.102

7.  Dose modification factors for 192Ir high-dose-rate irradiation using Monte Carlo simulation.

Authors:  Bassel Kassas; Firas Mourtada; John L Horton; Richard G Lane; Thomas A Buchholz; Eric A Strom
Journal:  J Appl Clin Med Phys       Date:  2006-08-24       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.